It is entirely possible that the first effective SARS-CoV-2 vaccine is developed in Australia, with an Australian firm securing patent rights to the vaccine. If that occurs, it is important to remember that a patent is not an impenetrable fortress. Patent laws already contain mechanisms to enable “special access” to patented pharmaceuticals and other technologies, including (perhaps especially) in times like this, say James Neil and Richard Hoad of Clayton Utz.
LG Electronics has lost its opposition to Samsung Electronic’s registration for its ‘Samsung QLED’ trade mark despite IP Australia acknowledging that Samsung’s phones did not contain QLED technology.
The television broadcaster behind the cult cooking show Iron Chef has lost its opposition to an ‘Iron Chef’ trade mark application by an Aussie food delivery app developer, despite IP Australia finding the show had garnered a “moderate reputation” among Australian viewers.
Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding the primary judge had erred by ruling that proof of intention was required for Swiss-style claims.
Motorola has slammed Chinese radio manufacturer Hytera’s “disruptive and unsatisfactory” request to adjourn a highly anticipated copyright trial over the alleged theft of source code which is due to begin in three weeks.
A delegate of IP Australia has tossed opposition by veterinary pharmaceutical company Norbrook Laboratories to a patent by rival animal health specialist Bayer New Zealand for a bovine antiseptic treatment.
Drug manufacturer Janssen wants to expand its high stakes case against Juno Pharmaceuticals over its HIV drug Prezista, alleging Juno’s plans to launch a generic version of the drug threaten another one of its patents.
Telstra has been ordered to provide technology company Siemens Industry Software with all documents relating to the identity of account holders who may have infringed Siemensā copyright.
A judge has rejected new evidence sought to be advanced by Hytera Communications in its IP battle with Motorola that Motorola deliberately delayed notifying Hytera of possible theft of its source code because it wanted to improve its market position.
Ariosa Diagnostics is fighting to revoke a patent for noninvasive prenatal test owned by Sequenom, arguing it merely describes how to extract “incorporeal” genetic information that is naturally found within the DNA of an unborn foetus.